- Tactile Systems Technology, Inc. reported strong second-quarter results, with earnings per share (EPS) of $0.34 significantly beating analyst estimates of $0.14.
- The medical technology company surpassed revenue expectations, achieving $85.71 million in total revenue, marking a 9% increase year-over-year, primarily driven by its lymphedema business.
- Demonstrating robust financial health, the company maintains a price-to-earnings (P/E) ratio of 26.49, a low debt-to-equity ratio of 0.06, and a strong current ratio of 4.12.
Tactile Systems Technology, Inc. (NASDAQ: TCMD), which operates as Tactile Medical, is a leading medical technology company. It specializes in developing and providing at-home therapy devices for patients with chronic diseases. The company's main business segments include its lymphedema products and its airway-clearance systems, such as the AffloVest, catering to the growing demand in the healthcare sector.
On August 10, 2026, the company reported strong second-quarter financial results. The company announced an earnings per share (EPS) of $0.34, which significantly beat the analyst consensus estimate of $0.14. This impressive performance represents a large earnings surprise of 142.86%, as detailed in a report from Zacks, highlighting the company's operational efficiency.
The company also surpassed revenue expectations for the quarter. It reported total revenue of $85.71 million, slightly ahead of the estimated $85.52 million. This marks a 9% increase in total revenue compared to the same period last year, when it was $78.90 million, showcasing consistent growth in its market.
The primary driver of this growth was the company's lymphedema business, which saw its revenue increase by 12% to $73.60 million. However, its airway-clearance revenue declined by 7% to $12.10 million. As highlighted by Seeking Alpha, this was due to inventory adjustments by partners during a new product launch for its airway clearance devices.
Looking at its financial health and for potential investment analysis, the company has a price-to-earnings (P/E) ratio of 26.49 and a low debt-to-equity ratio of 0.06. The company also maintains a current ratio of 4.12. This ratio measures a company's ability to pay its short-term obligations, with a higher number suggesting a stronger financial position, making it an attractive medical technology stock.